At a glance
ClinicalIndex Comparison RecordN/ACompleted· 522 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Romania
In Brief
An observational study for Chronic Hepatitis C. Completed, enrolled 522 participants.
Detailed Summary
This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), + dasabuvir (DSV), +/- ribavirin (RBV) in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Romania.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
CollaboratorsIST GmbH, Germany
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJul 2016
Primary CompletionAug 2017
TodayJul 2026
First PostedJun 21, 2016
Enrollment StartJul 14, 2016
Primary CompletionAug 4, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.0 years ago